سعر سيركبروف 100مجم 20 اقراص 2022

Sercprove 100 mg is an Egyptian cilostazol tablet product by Unipharma, supplied as 20 tablets (2 strips); cilostazol is a phosphodiesterase-3 inhibitor used to reduce the symptoms of intermittent claudication.

• Reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.Population: Adults with intermittent claudicationDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (at least 2% and at least twice placebo on 100 mg twice daily): headache, diarrhoea, abnormal stools and palpitation; dizziness, peripheral oedema, rhinitis, infection and tachycardia were also reported in controlled trials.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Heart failure of any severity (boxed warning: PDE3 inhibitors have caused decreased survival compared with placebo in class III-IV heart failure).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to cilostazol or any component of the tablets (e.g. anaphylaxis, angioedema).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• May induce tachycardia, palpitation, tachyarrhythmia or hypotension.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Thrombocytopenia or leukopenia progressing to agranulocytosis has been reported when cilostazol was not immediately discontinued; agranulocytosis is reversible on discontinuation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not studied in haemostatic disorders or active pathological bleeding; avoid use in these patients (reversible inhibition of platelet aggregation).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong or moderate CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, erythromycin, diltiazem)Increase cilostazol exposure; reduce the dose to 50 mg twice daily.DailyMed (U.S. National Library of Medicine)
• CYP2C19 inhibitors (e.g. ticlopidine, fluconazole, omeprazole)Increase exposure to cilostazol or its active metabolites; reduce the dose to 50 mg twice daily.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; cilostazol was teratogenic in rats at doses greater than 5 times the maximum recommended human dose (body surface area basis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cilostazol: Cilostazol and several of its metabolites inhibit phosphodiesterase III, increasing cAMP; this inhibits platelet aggregation and causes vasodilation.